CTLA4 and neoplasm: To explore whether combination with anti-CTLA-4 could enhance the antitumor efficacy of YST-OVH, we performed i.t. injection of YST-OVH with intraperitoneal (i.p.)injection of anti-CTLA-4 to treat the Hepa1-6 bilateral flank tumor model (figure 6A).